Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NB1000S,NB2000P
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Tencent
Deal Size : $43.5 million
Deal Type : Series B Financing
Details : The proceeds will be used to advance both Novome’s clinical hyperoxaluria candidate, NOV001, through an ongoing Phase 2a clinical trial and multiple Genetically Engineered Microbial Medicines (GEMMs) candidates for the potential treatment of inflammato...
Brand Name : NOV-001
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 13, 2022
Lead Product(s) : NB1000S,NB2000P
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Tencent
Deal Size : $43.5 million
Deal Type : Series B Financing
Lead Product(s) : NB1000S,NB2000P
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novome Biotechnologies Reports Positive Results from a Phase 1 Study of NOV-001
Details : NOV-001 is an investigational combination product composed of NB1000S and NB2000P. Preclinical studies of NOV001 showed consistent and robust reduction in urine oxalate levels in multiple animal models of disease.
Brand Name : NOV-001
Molecule Type : Large molecule
Upfront Cash : Not Applicable
November 17, 2021
Lead Product(s) : NB1000S,NB2000P
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Genetically Engineered Microbial Medicines
Therapeutic Area : Gastroenterology
Study Phase : Discovery
Sponsor : Genentech
Deal Size : $605.0 million
Deal Type : Collaboration
Details : Under the terms of the agreement, Novome will have responsibility for research activities up to initiation of IND-enabling preclinical studies for this multi-target collaboration.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : $15.0 million
November 10, 2021
Lead Product(s) : Genetically Engineered Microbial Medicines
Therapeutic Area : Gastroenterology
Highest Development Status : Discovery
Sponsor : Genentech
Deal Size : $605.0 million
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Study Phase : Discovery
Sponsor : DCVC Bio
Deal Size : $33.0 million
Deal Type : Series A Financing
Details : The financing will be used to advance the company’s lead hyperoxaluria program through Phase 1 clinical proof-of-concept work, as well as to expand its (GEMMs) platform.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 07, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Nephrology
Highest Development Status : Discovery
Sponsor : DCVC Bio
Deal Size : $33.0 million
Deal Type : Series A Financing
LOOKING FOR A SUPPLIER?